Lupin Limited – Investor Presentation Summary

Key Operational Highlights

  • India business grew ~14% YoY, achieving its highest quarterly sales in the last six quarters.
  • Diagnostics platform served around 7+ lakh patients during the quarter.
  • ~10,000 cardiac patients were onboarded onto the digital patient support platform during the quarter.
  • The India field force consists of 8,700+ representatives.
  • Key drivers include a focus on chronic therapies, digital offerings, and diagnostics expansion.

Segment-wise Performance

Not Specified

Financial Highlights

Revenue: Rs. 82,172 crore (Net Sales)

EBITDA: Rs. 24,635 crore (30.0% margin on Net Sales, excludes Forex and Other Income)

PAT: Rs. 14,150 crore (Net Income after adjusting NCI stake, 17.2% margin)

YoY comparison (Q1 FY27 vs Q1 FY26):

  • Net Sales growth: 33.3% (from Rs. 61,638 crore)
  • EBITDA growth: 50.1% (from Rs. 16,414 crore)
  • Net Income growth: 16.1% (from Rs. 12,191 crore)

QoQ comparison (Q1 FY27 vs Q4 FY26):

  • Net Sales growth: 11.2% (from Rs. 73,919 crore)
  • EBITDA growth: 13.5% (from Rs. 21,710 crore)
  • Net Income change: (3.1%) (from Rs. 14,604 crore; Q4 FY26 included a net one-time exceptional expense of INR 1,313 Mn)

Drivers of financial performance: Strong revenue growth and operational performance.

Key Risks: General industry, geopolitical and market conditions, domestic and international economic conditions, interest rate and currency exchange fluctuations, product development and regulatory risks.

Geographical Revenue Split

United States: Includes IP income. Market share of 4.2% (IQVIA Qtr TRx June-26).

India: Comprises Rx + OTC + Diagnostics + Others. Market share of 2.8% (IQVIA MAT June'26).

Other Developed Markets: Comprises Canada, Australia, Europe & Others.

Emerging Markets: Comprises LATAM, South Africa, Philippines & RoW.

Balance Sheet Snapshot

Not Specified

Capex & Cash Flow Health

Not Specified

Strategic & R&D Initiatives

Investments in Innovation: R&D is pivoting towards complex generics and biosimilars. Pipeline includes 20 complex product launches in inhalation, injectables, and ophthalmics by 2028. Goals include 5 biosimilar filings and 10 novel complex product launches in India by 2028.

Expected impact on growth: Aim to build a global presence in inhalation and become a fully vertically-integrated biosimilars company.

Strategic Rationale: Expanding into high-growth complex generic and biosimilar markets.

Industry Trends & Business Environment

Not Specified

Management Commentary & Growth Outlook

Strategic Outlook: The India business (IRF) is poised to outperform the Indian Pharmaceutical Market (IPM) by 1.2-1.3x. The company aims to maximize chronic focus with ~70% share by FY31.

FY Guidance: Plan to launch 20+ products in India in FY27.

Risks and Opportunities: General risks related to industry, geopolitics, economics, and product development are acknowledged.

ESG Updates

  • Lupin achieved a global #1 ESG rating in the pharma sector from S&P Global with a score of 91/100.
  • 48% share of renewable energy achieved.
  • 5 years of water positivity in a row.
  • Featured in TIME World's Most Sustainable Companies 2026 List and included in Dow Jones Best-in-Class Indices.
  • 22,400+ patients covered under the "Lives Program".
  • Target of 50,000 employee volunteering hours by 2030 (35,400+ hours achieved).
  • Target of 3 million patient education & awareness beneficiaries by 2030 (980,000 patients reached).

#CompanyName: Lupin

#EventTags: #FinancialResults #EarningsUpdate #InvestorPresentation #ESG #RegulatoryApprovals

#SentimentTag: #Positive